Journal article
CA 15-3/MUC1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo
Abstract
Background: Circulating levels of cancer antigen (CA) 15-3, a tumor marker and regulator of cellular metabolism, were reduced by metformin in a nonrandomized neoadjuvant study. We examined the effects of metformin (vs placebo) on CA 15-3 in participants of MA.32, a phase III randomized trial in early-stage breast cancer.
Methods: A total of 3649 patients with T1-3, N0-3, M0 breast cancer were randomly assigned; pretreatment and 6-month …
Authors
Goodwin PJ; Dowling RJO; Ennis M; Chen BE; Parulekar WR; Shepherd LE; Gelmon KA; Whelan TJ; Ligibel JA; Hershman DL
Journal
JNCI Cancer Spectrum, Vol. 5, No. 5,
Publisher
Oxford University Press (OUP)
Publication Date
September 1, 2021
DOI
10.1093/jncics/pkab066
ISSN
2515-5091